Publication | Closed Access

Economic Evaluation of Bivalirudin With or Without Glycoprotein IIb/IIIa Inhibition Versus Heparin With Routine Glycoprotein IIb/IIIa Inhibition for Early Invasive Management of Acute Coronary Syndromes

ThrombosisCardiovascular DiseasePharmacologyCardiovascular PharmacologyPlatelet AntagonistCardiologyPharmacotherapyEarly Invasive ManagementPublic HealthEconomic EvaluationMedicineAnticoagulantAtherosclerosisAcute Coronary SyndromesCoronary Artery DiseaseAcute Myocardial Infarction